The two-drug regimen dolutegravir plus lamivudine has demonstrated durable efficacy and a high barrier to resistance in phase III clinical trials with data up to 3 years, and this review summarizes data on the effectiveness and safety of dolutegravir plus lamivudine in real-world settings.

Virologic suppression was achieved and maintained with dolutegravir plus lamivudine in a wide variety of people with HIV-1, including those simplifying from a three-drug regimen.

Rates of virologic failure were low in virologically suppressed individuals who switched to dolutegravir plus lamivudine, and rates of discontinuation due to adverse events were low and consistent with previously observed trial data.

Results from this systematic literature review demonstrate that real-world effectiveness and safety of dolutegravir plus lamivudine in clinical practice support data from randomized controlled trials regarding high rates of virologic response, low rates of discontinuation due to adverse events, and a high barrier to resistance.